Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Spark Therap (ONCE)

Spark Therap (ONCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,375,056
  • Shares Outstanding, K 38,523
  • Annual Sales, $ 64,730 K
  • Annual Income, $ -78,820 K
  • 60-Month Beta 2.05
  • Price/Sales 65.92
  • Price/Cash Flow N/A
  • Price/Book 12.63
Trade ONCE with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.56
  • Most Recent Earnings -1.67 on 02/19/19
  • Next Earnings Date 11/26/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.47
  • Number of Estimates 3
  • High Estimate -1.13
  • Low Estimate -1.84
  • Prior Year -1.75
  • Growth Rate Est. (year over year) +16.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
109.25 +0.73%
on 12/04/19
113.90 -3.38%
on 12/16/19
-0.76 (-0.69%)
since 11/15/19
3-Month
95.92 +14.73%
on 10/02/19
113.90 -3.38%
on 12/16/19
+5.65 (+5.41%)
since 09/17/19
52-Week
34.53 +218.71%
on 12/26/18
114.20 -3.63%
on 03/12/19
+69.70 (+172.74%)
since 12/17/18

Most Recent Stories

More News
Spark Therapeutics' SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date

Factor VIII (FVIII) expression was sustained in 16 of 18 participants with up to 4 years of follow-up to the administration of SPK-8011

ONCE : 110.05 (-3.10%)
Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care

- Roche will present the final analysis from the phase IIIb STASEY study, reinforcing the safety and efficacy profile of Hemlibra in a broad range of people with haemophilia A with factor VIII inhibitors1...

ONCE : 110.05 (-3.10%)
Retinal Biologics Market worth USD 34,891.44 Million by 2027, at 11.5% CAGR | Market Research Future (MRFR)

Retinal Biologics Market Overview:

ABBV : 118.19 (+0.55%)
AMGN : 247.72 (+1.22%)
REGN : 586.35 (-0.09%)
ONCE : 110.05 (-3.10%)
Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform

Collaboration combines Senti Bio's leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics' investigational gene therapies targeting...

ONCE : 110.05 (-3.10%)
Gene Therapy Market Size 2021 | To Exhibit 33.6% CAGR and Hit USD 35.67 billion by 2027

The global gene therapy market is set to gain momentum from the rising incidence of different types of cancer. The field of this therapy is undergoing several technological advancements that would help...

AMGN : 247.72 (+1.22%)
GILD : 69.02 (+0.54%)
GSK : 39.51 (+0.71%)
JAZZ : 173.93 (+0.06%)
SRPT : 66.79 (-3.36%)
ONCE : 110.05 (-3.10%)
Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer

Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today...

ONCE : 110.05 (-3.10%)
Europe Cell and Gene Therapy Market 2021-2026: Opportunities in CMO Offering Vector-Manufacturing Services Robust Cell & Gene Therapy Pipeline Increase In Strategic Acquisitions

, /PRNewswire/ -- The report has been added to offering.

AMGN : 247.72 (+1.22%)
GILD : 69.02 (+0.54%)
ONCE : 110.05 (-3.10%)
Europe Cell and Gene Therapy Market Report 2021-2026: Prominent Players are Novartis, Spark Therapeutics, Amgen, Gilead Sciences & Organogenesis

The "Europe Cell and Gene Therapy Market - Industry Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

AMGN : 247.72 (+1.22%)
GILD : 69.02 (+0.54%)
NVS : 91.57 (+0.54%)
ONCE : 110.05 (-3.10%)
Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress

Preliminary data from four participants who received investigational SPK-8016 at a dose of 5X10 vg/kg and have no history of FVIII inhibitors show no serious adverse events and stable and durable factor...

ONCE : 110.05 (-3.10%)
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision

Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision

ONCE : 110.05 (-3.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 114.08
1st Resistance Point 113.82
Last Price 110.05
1st Support Level 113.39
2nd Support Level 113.22
3rd Support Level N/A

See More

52-Week High 114.20
Last Price 110.05
Fibonacci 61.8% 83.77
Fibonacci 50% 74.36
Fibonacci 38.2% 64.96
52-Week Low 34.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar